Multiple-drug Resistance in Ewing’s Sarcoma and Peripheral Primitive Neuroectodermal Tumors

1994 ◽  
Vol 102 (1) ◽  
pp. 1-2 ◽  
Author(s):  
Timothy J. Triche
Keyword(s):  
Drug Resistance ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Multiple Drug Resistance ◽  
Multiple Drug ◽  
Primitive Neuroectodermal Tumors ◽  
Neuroectodermal Tumors ◽  
Peripheral Primitive Neuroectodermal Tumors

Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors in Bronchus

2019 ◽  
Vol 357 (1) ◽  
pp. 75-80 ◽  
Author(s):  
Jun Chen ◽  
Tao Yuan ◽  
Xiao Liu ◽  
Bei Hua ◽  
Chenfeng Dong ◽  
...  
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Primitive Neuroectodermal Tumors ◽  
Neuroectodermal Tumors ◽  
Peripheral Primitive Neuroectodermal Tumors

Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.

1995 ◽  
Vol 13 (11) ◽  
pp. 2796-2804 ◽  
Author(s):  
B H Kushner ◽  
P A Meyers ◽  
W L Gerald ◽  
J H Healey ◽  
M P La Quaglia ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Young Adults ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
High Dose ◽  
Primitive Neuroectodermal Tumors ◽  
Poor Risk ◽  
Neuroectodermal Tumors ◽  
Intensive Use ◽  
Peripheral Primitive Neuroectodermal Tumors

PURPOSE To improve the prognosis of patients with poor-risk peripheral primitive neuroectodermal tumors (pPNETs; including peripheral neuroepithelioma and Ewing's sarcoma), while testing the feasibility of intensive use in adolescents and young adults of high-dose cyclophosphamide, doxorubicin, and vincristine (HD-CAV). PATIENTS AND METHODS This report concerns previously untreated patients with newly diagnosed pPNET deemed poor-risk because of a tumor volume more than 100 cm3 or metastases to bone or bone marrow. The P6 protocol consists of seven courses of chemotherapy. Courses 1, 2, 3, and 6 include 6-hour infusions of cyclophosphamide on days 1 and 2 for a total of 4,200 mg/m2 per course (140 mg/kg per course for patients < 10 years old), plus 72-hour infusions of doxorubicin 75 mg/m2 and vincristine 2.0 mg/m2 beginning on day 1 (HD-CAV). Courses 4, 5, and 7 consist of 1-hour infusions of ifosfamide 1.8 g/m2/d and etoposide (VP-16) 100 mg/m2/d, for 5 days. Granulocyte colony-stimulating factor (G-CSF) and mesna are used. Courses start after neutrophil counts reach 500/microL and platelet counts reach 100,000/uL. Surgical resection follows course 3 and radiotherapy follows completion of all chemotherapy. RESULTS Among the first 36 consecutive assessable patients (median age, 17 years), HD-CAV achieved excellent histopathologic or clinical responses in 34 patients and partial responses (PRs) in two patients. For 24 patients with locoregional disease, the 2-year event-free survival rate was 77%; adverse events were two locoregional relapses, one distant relapse, and one secondary leukemia. All six patients with metastatic disease limited to lungs achieved a complete response (CR) and did not relapse; one is in remission 36+ months from diagnosis, but the other patients are not assessable in terms of long-term efficacy of the P6 protocol because of short follow-up time (n = 3), additional systemic therapy (bone marrow transplantation), or septic death (autopsy showed no residual pPNET). All six patients with widespread metastases had major responses, including eradication of extensive bone marrow involvement, but distant relapses ensued. Myelosuppression was severe, but most patients received the first three courses of HD-CAV within 6 to 7 weeks. Major nonhematologic toxicities were mucositis and peripheral neuropathy. CONCLUSION Excellent antitumor efficacy and manageable toxicity support the dose-intensive use of HD-CAV for pPNET in children, as well as in young adults. Consolidation of remissions of pPNET metastatic to bone and bone marrow remains a therapeutic challenge.

Intraspinal Ewing’s sarcoma/primitive neuroectodermal tumors

2011 ◽  
Vol 18 (5) ◽  
pp. 601-606 ◽  
Author(s):  
Yong Yan ◽  
Tao Xu ◽  
Juxiang Chen ◽  
Guohan Hu ◽  
Yicheng Lu
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Primitive Neuroectodermal Tumors ◽  
Neuroectodermal Tumors

scholarly journals Importance of studying primitive neuroectodermal tumors and extraosseous Ewing's sarcoma of the vagina and vulva (Review)

2021 ◽  
Vol 21 (2) ◽  
Author(s):  
Adeline Tintila ◽  
Bogdan Doroftei ◽  
Delia Grab ◽  
Gabriela Simionescu ◽  
Emil Anton ◽  
...  
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Primitive Neuroectodermal Tumors ◽  
Neuroectodermal Tumors ◽  
Extraosseous Ewing’S Sarcoma

scholarly journals EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.

1994 ◽  
Vol 94 (2) ◽  
pp. 489-496 ◽  
Author(s):  
M Giovannini ◽  
J A Biegel ◽  
M Serra ◽  
J Y Wang ◽  
Y H Wei ◽  
...  
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Primitive Neuroectodermal Tumors ◽  
Fusion Transcripts ◽  
Neuroectodermal Tumors
Sign in / Sign up

Export Citation Format

Share Document